Avid Bioservices Inc (CDMO)

[biopharm]

SBU Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent

June 7, 2012

Must be close on all fronts... including MRI

Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs

Liang Zhang,
Zhongwei Zhang,
Ralph P. Mason,
Jann N. Sarkaria &
Dawen Zhao


Received
17 November 2014
Accepted
19 March 2015
Published
12 May 2015

Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

...
..

Affiliations

Radiology, UT Southwestern Medical Center, Dallas, TX
Liang Zhang, Zhongwei Zhang, Ralph P. Mason & Dawen Zhao
Radiation Oncology, Mayo Clinic, Rochester, MN
Jann N. Sarkaria

Contributions

L.Z. and D.Z. designed research; L.Z., Z.Z. and D.Z. performed the research; L.Z., Z.Z. and D.Z. analyzed data; L.Z., R.M., J.S., and D.Z. wrote the paper.
Competing financial interests

The authors declare no competing financial interests.
Corresponding author

Correspondence to:

Dawen Zhao


http://www.nature.com/srep/2015/150512/srep09874/full/srep09874.html